Consequences of chromosomal abnormalities in tumor development

Annual Review of Genetics
I Sánchez-García

Abstract

This article highlights recent advances in the molecular structure and function of proteins that are activated or created by chromosomal abnormalities and discusses their possible role in tumor development. The molecular characterization of these proteins has revealed that tumor-specific fusion proteins are the consequence of most chromosome translocations associated with leukemias and solid tumors. An emerging common theme is that creation of these proteins disrupts the normal development of tumor-specific target cells by blocking apoptosis. These insights identify these chromosomal translocation-associated genes as potential targets for improved cancer therapies.

References

Dec 1, 1992·Genes & Development·L D KerrI M Verma
Apr 3, 1992·Cell·G I EvanD C Hancock
Oct 1, 1991·The Journal of Experimental Medicine·B TyckoJ Sklar
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M A KennedyT H Rabbitts
May 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J C ReedK Bradley
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A PerkinsS Cory
Dec 1, 1994·Genes, Chromosomes & Cancer·I PanagopoulosF Mitelman
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T R GolubD G Gilliland
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·R BaffaC M Croce
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·I Sánchez-García, G Grütz
Jun 1, 1995·Genes & Development·J M Bishop
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·W L GeraldM Ladanyi
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·V E ArcherT H Rabbitts
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·M ZionY Ben-Neriah
Nov 10, 1994·Nature·T H Rabbitts
Sep 1, 1994·Trends in Genetics : TIG·I Sánchez-García, T H Rabbitts

❮ Previous
Next ❯

Citations

Apr 14, 2005·Seminars in Cancer Biology·P A Pérez-Mancera, I Sánchez-García
Oct 6, 2001·Trends in Biotechnology·C Cobaleda, I Sánchez-García
May 16, 2009·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·César Cobaleda, Isidro Sánchez-García
Sep 17, 2005·Leukemia Research·Adán ValladaresFabio Salamanca-Gómez
Feb 20, 2004·Human Mutation·Shaun S AbeysingheDavid N Cooper
Mar 16, 2002·Oncogene·Pedro Antonio Pérez-ManceraIsidro Sánchez-García
Mar 1, 2005·Oncogene·Pedro Antonio Pérez-ManceraIsidro Sánchez-García
Jan 10, 2008·British Journal of Cancer·M Pérez-CaroI Sánchez-García
Sep 2, 1999·British Journal of Cancer·P A Lazo
Sep 20, 2006·Oncogene·M Pérez-CaroI Sánchez-García
Oct 7, 2005·Human Molecular Genetics·Pedro Antonio Pérez-ManceraIsidro Sánchez-García
Jun 7, 2008·Expert Review of Anticancer Therapy·Radha Todd, John Lunec
May 10, 2019·PloS One·Ignacio García-TuñónManuel Sánchez-Martín
Dec 12, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Maria RibasMiguel A Peinado
Aug 21, 2003·Journal of Biomedical Science·Asad U Khan, Sunil K Lal
Jan 24, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Asad U Khan

❮ Previous
Next ❯

Methods Mentioned

BETA
cytogenetic

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.